Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Venous Thromboembolism 3Neoplasms 3Venous Thrombosis 2Thrombosis 2Pancreatic Neoplasms 2Thromboembolism 1Stomach Neoplasms 1Pulmonary Embolism 1Ovarian Neoplasms 1Obesity 1Multiple Myeloma 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Embolism and Thrombosis 1Embolism 1Duodenal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

Dexamethasone 337Bortezomib 187Lenalidomide 186Cyclophosphamide 166Melphalan 124Calcium Dobesilate 108daratumumab 95fludarabine phosphate 69carfilzomib 69pomalidomide 68Peripheral Blood Stem Cell Transplantation 64Filgrastim 56Thalidomide 55Busulfan 53Mycophenolic Acid 52Tacrolimus 45Granulocyte Colony-Stimulating Factor 45ixazomib 43fludarabine 42Whole-Body Irradiation 40Cyclosporine 35Etoposide 33dexamethasone acetate 31Antilymphocyte Serum 31isatuximab 29dexamethasone 21-phosphate 26Prednisone 26elotuzumab 25Biopsy 25auricularum 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Multiple Myeloma × Dalteparin × Clear all
NCT01518465 2017-11-29

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

University of Southern California

Phase 2 Terminated
13 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡